Research field (2)：
Molecular biology
, Otorhinolaryngology
Research keywords (4)：
がんの浸潤・転移
, シスプラチン不耐頭頸部癌症例への治療最適化
, 免疫チェックポイント阻害剤治療と好酸球数変化の関連性
, PLOD2
Research theme for competitive and other funds (2)：
2022 - 2025 Study on the process of carcinogenesis by HPV infection comparing pharynx and cervix
2022 - 2025 Development of novel head and neck cancer therapy focusing PLOD2 suppression driven by cyclin-dependent kinase inhibition.
Papers (117)：
Yuki Ohno, Yushi Ueki, Shusuke Oshima, Jo Omata, Yusuke Yokoyama, Takeshi Takahashi, Ryusuke Shodo, Keisuke Yamazaki, Arata Horii. Aortic rupture following acute aortitis in a patient with head and neck carcinoma treated with nivolumab: a rare but severe immune-related adverse event. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery. 2024. 281. 4. 2037-2040
Yushi Ueki, Shusuke Ohshima, Yusuke Yokoyama, Takeshi Takahashi, Ryusuke Shodo, Keisuke Yamazaki, Kohei Ohtaki, Kohei Saijo, Ryoko Tanaka, Takafumi Togashi, et al. Multicenter prospective phase II trial of concurrent chemoradiotherapy with weekly low-dose carboplatin for cisplatin-ineligible patients with advanced head and neck squamous cell carcinoma. International journal of clinical oncology. 2024. 29. 1. 20-26
Ryusuke Shodo, Keisuke Yamazaki, Yushi Ueki, Takeshi Takahashi, Yusuke Yokoyama, Arata Horii. Sarcopenia Index Predicts Short-Term Prognosis of Head and Neck Squamous Cell Carcinoma. Nutrition and cancer. 2024. 76. 2. 149-159
Yusuke Yokoyama, Yushi Ueki, Shusuke Ohshima, Jo Omata, Takeshi Takahashi, Ryusuke Shodo, Keisuke Yamazaki, Arata Horii. Genomic analysis of radiation-induced osteosarcoma in the maxilla. Oral Oncology Reports. 2023. 8. 100107-100107
Yushi Ueki, Shusuke Ohshima, Jo Omata, Yusuke Yokoyama, Takeshi Takahashi, Ryusuke Shodo, Keisuke Yamazaki, Arata Horii. Role of eosinophilia in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab: Prediction of immune-related adverse events and favorable outcome. Cancer medicine. 2023. 12. 22. 20810-20820
